SH2D1A and X-linked lymphoproliferative syndrome: Kohn and colleagues develop a potential gene therapy treatment for X-linked lymphoproliferative disease (XLP1), caused by SH2D1A gene mutations affecting SAP, using a lentiviral vector (LV) expressing therapeutic SAP.